Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study

Psychopharmacology

Volumn 142, Issue 1, 1999, Pages 41-50

  Gouzoulis Mayfrank, E ^a   Thelen, B ^b,d   Habermeyer, E ^a   Kunert, H J ^a,c   Kovar, K A ^a   Lindenblatt, H ^a   Hermle, L ^c   Spitzer, M ^d   Sass, H ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Psychiatric Hospital Christophsbad   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Ecstasy; Entactogens; MDE; Methamphetamine; Psilocybin; Psychopathology

Indexed keywords

3,4 METHYLENEDIOXYETHYLAMPHETAMINE; AMPHETAMINE DERIVATIVE; METHAMPHETAMINE; PSILOCYBINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MENTAL DISEASE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ACUTE-PHASE REACTION; ADULT; AGED; AUTONOMIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; PSILOCYBINE; PSYCHOPATHOLOGY;

EID: 0032967408     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050860     Document Type: Article

References (57)

1. Aghajanian GK (1994) LSD and phenethylamine hallucinogens: common sites of neuronal action. In: Pletscher A, Ladewig D (eds) 50 years of LSD. Current status and perspectives of hallucinogens. Parthenon, New York, London, pp 27-41
2. Allen RP, McCann UD, Ricaurte GA (1993) Persistent effects of 3,4-methylenedioxy-methamphetamine (MDMA, "Ecstasy") on human sleep. Sleep 16:560-564
3. Angrist B (1994) Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS (eds) Amphetamine and its analogs. Pharmacology, toxicology and abuse. Academic Press, San Diego, pp 387-414
4. Angrist B, Corwin J, Bartlik B, Cooper T (1987) Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368
5. Battaglia G, Brooks BP, Kulsakdinum C, DeSouza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymetamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163
6. Bech P (1988) Rating scales for mood disorders: applicability, consistency and construct validity. Acta Psychiatr Scand 78 [Suppl 345]:45-55
7. Benazzi F, Mazzoli M (1991) Psychiatric illness associated with "Ecstasy" (letter). Lancet 338:1520
8. Brown WA, Corriveau DP, Ebert MH (1978) Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology 58:189-195
9. Cohen RS (1995) Subjective reports on the effects of the MDMA ("Ecstasy") experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 19:1137-1145
10. Creighton FJ, Black DL, Hyde CE (1991) "Ecstasy" psychosis and flashbacks. Br J Psychiatry 159:713-715
11. Davison D, Parrott AC (1997) Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:221-226
12. Dittrich A (1985) Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. Enke, Stuttgart
13. Dittrich A, von Arx S, Staub S (1985) International study on altered states of consciousness (ISASC). Summary of the results. German J Psychol 9:319-339
14. Dommisse CS, Schulz SC, Narasimhachari N, Blackard WG, Hamer RM (1984) The neuroendocrine and behavioral response to dextroamphetamine in normal individuals. Biol Psychiatry 19:1305-1315
15. Dowling GP, McDonough ET, Bost RO (1987) "Eve" and "ecstasy" : a report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615-1617
16. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoact Drugs 18: 335-340
17. Fahrenberg J, Selg H, Hampel R (1984) Das Freiburger Persönlichkeitsinventar FPI-R. Hofgreve, Göttingen
18. Fuller RW (1981) Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32:118-127
19. Gamma A, Buck A, Hell D, Vollenweider FX (1997) 3,4-Methylenedioxymethamphetamine (MDMA) alters the pattern of regional cerebral blood flow (rCBF) in drug-naive volunteers. Pharmacopsychiatry 30:170
20. Gouzoulis E, Steiger A, Ensslin M, Kovar K-A, Hermle L (1992) Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; "Eve") in healthy volunteers. Biol Psychiatry 32: 1108-1117
21. Gouzoulis E, Bardeleben Uv, Rupp A, Kovar K-A, Hermle L (1993a) Neuroendocrine and cardiovascular effects of 3,4-methylenedioxyethamphetamine (MDE; "Eve") in healthy volunteers. Neuropsychopharmacology 8:187-193
22. Gouzoulis E, Borchardt D, Hermle L (1993b) A case of toxic psychosis induced by "Eve" (3,4-methylenedioxyethylamphetamine). Arch Gen Psychiatry 50:75
23. Gouzoulis-Mayfrank E (1998) Wirkungen und Risiken des Ecstasy-Konsums. Psychotrope und neurobiologische Wirkungen. In: Thomasius R (ed) Ecstasy - Wirkungen, Risiken, Interventionen. Enke, Stuttgart (in press)
24. Greer GR, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18: 319-327
25. Grob CS, Poland RE (1997) MDMA. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse. A comprehensive textbook, 3rd edn. Williams and Wilkins, Baltimore, Maryland, pp 269-275
26. Grob CS, Polland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73: 103-107
27. Gunne L-M (1977) Effects of amphetamines in humans. In: Martin WR (ed) Drug addiction II: amphetamine, psychotogen and marihuana dependence. Handbook of experimental pharmacology, vol 45/II. Springer, Berlin, Heidelberg, New York, pp 247-275
28. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 340: 384-387
29. Hermle L, Spitzer M, Borchardt D, Kovar K-A, Gouzoulis E (1993) Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8: 171-176
30. 3H-dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276
31. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
32. Kelly TH, Foltin RW, Fischman MW (1991) The effects of repeated amphetamine exposure on multiple measures of human behavior. Pharmacol Biochem Behav 38:417-426
33. King GR, Ellinwood EV (1992) Amphetamines and other stimulants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse. A comprehensive textbook, 3rd edn. Williams and Wilkins, Baltimore, Maryland, pp 247-270
34. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol abuse 18: 331-341
35. Laux L, Glanzmann P, Schaffner P, Spielberger CD (1981) Das State-Trait-Angstinventar (STAI). Beltz, Weinheim
36. Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine. J Nerv Ment Dis 180:345-352
37. McCann UD, Ricaurte GA (1992) MDMA ("Ecstasy") and panic disorder: induction by a single dose. Biol Psychiatry 32:950-953
38. McCann DU, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10:129-138
39. Meltzer HY, Fessier RG, Simonovic M, Fang VS (1978) The effect of mescaline, 3,4-dimethoxylphenethylamine and 2,5-dimethoxy-4-methylamphetamine on rat plasma prolactin: evidence for serotonergic mediation. Life Sci 23:1185-1192
40. Milroy CM, Clark JC, Forrest ARW (1996) Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol 49:149-153
41. Nash JF, Meltzer HY (1990) Neuroendocrinological effects of MDMA in the rat. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer Academic, Boston, pp 225-239
42. Nash JF, Meltzer HY, Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873-879
43. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18:305-313
44. Nichols DE (1994) Medical chemistry and structure-activity relationships. In: Cho AK, Segal DS (eds) Amphetamine and its analogs. Pharmacology, toxicology and abuse. Academic Press, San Diego, pp 3-41
45. Pallanti S, Mazzi D (1992) MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 32:91-95
46. Parrott AC, Stuart M (1997) Ecstasy (MDMA), amphetamine, and LSD: comparative mood profiles in recreational polydrug users. Hum Psychopharmacol 12:501-504
47. Pechnick RN, Ungerleider JT (1997) Hallucinogens. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse. A comprehensive textbook, 3rd edn. Williams and Wilkins, Baltimore, Maryland, pp 230-238
48. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphe-tamine in recreational users. Neuropsychopharmacology 1:273-277
49. Saunders N (1995) Dance drugs. In: Saunders N (ed) Ecstasy and the dance culture. Saunders, Exeter, UK, pp 148-161
50. Solowji N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of "ecstasy" users and their experiences with the drug. Br J Addict 87:1161-1172
51. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36:2297-2303
52. Strassman RJ, Quails CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108
53. Van de Kar LD, Karteszi M, Bethea CL, Ganong WF (1985) Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 41:380-384
54. Vollenweider FX, Liechti M, Gamma A, Hell D, Geyer M (1997) Effects of MDMA ("Ecstasy") on sensorimotor gating, attention, and mood in healthy volunteers. Abstracts: International Congress on The State of the Art in Psychiatry, June 19-21, 1997, Basel, Switzerland, S. 28
55. Whitaker-Azmitia PM, Aronson TA (1989) "Ecstasy" (MDMA)-induced panic (letter). Am J Psychiatry 146:119
56. Zahn TP, Rapoport JL, Thompson CL (1981) Autonomic effects of dextroamphetamine in normal men: implications for hyperactivity and schizophrenia. Psychiatr Res 4:39-47
57. Zerssen D von (1976) Die Beschwerden-Riste. Manual. Beltz, Weinheim